Sana Biotechnology

### Executive Summary Sana Biotechnology raised $233.0M in a Regulation D private placement, with first sale on 2025-10-12. The filing lists Andreessen Horowitz and Sands Capital as related persons, signaling strong institutional backing for synthetic biology and intracellular mRNA delivery. ### Investor Edge Watch for subsequent D/A amendments indicating additional capital or changes in terms, and monitor for any public filings (e.g., S-1) that could signal an IPO or reverse merger. ### Sector capital positioning This large private raise in synthetic biology and mRNA delivery signals sustained capital flow into next-generation genetic medicine platforms, particularly those with intracellular delivery capabilities. ### Convergence Signals No direct public signals (patents, contracts, legislation) are evident from the filing data alone. However, the involvement of top-tier VCs suggests potential for future public market exits or partnerships. ### Key Takeaways - Sana Biotechnology raised $233.0M in a private placement, with Andreessen Horowitz and Sands Capital as related persons. - The company operates in synthetic biology and intracellular mRNA delivery, a high-growth sector. - No public ticker exists; this is a private company filing a Form D. ### Risk Indicators & Flags No D/A amendments noted; the amount ($233.0M) is large for a private placement, which may indicate high capital burn or ambitious scale-up. Regulatory risks in synthetic biology and mRNA delivery are inherent. ### Verification & References Filing data from SEC EDGAR, accession number 0001702600-24-20095. Verify at https://www.sec.gov/cgi-bin/browse-edgar?company=Sana%20Biotechnology&type=D&action=getcompany. First sale date 2025-10-12, capital raised $233.0M.